We have observed
2 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 28, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Compositions monovalent for CD28 binding and methods of use
NMDA ANTAGONIST PRODRUGS